We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
UK regulators recorded a nearly 20 percent increase in complaints about drug advertisements in 2013 compared to 2012, with the majority of complaints coming from companies complaining about their competitors. Read More
A congressional committee is reviving an investigation into the FDA’s surveillance of employee emails, and is asking agency officials what the FDA has done to protect whistleblowers from harassment. Read More
Preliminary data from a late-stage trial of Eli Lilly’s type 2 diabetes drug dulaglutide positions the candidate as a major contender in the increasingly competitive drug class known as GLP-1. Read More
With analysts predicting skyrocketing sales for Gilead Sciences’ hepatitis C treatment Sovaldi, AbbVie has filed a patent infringement suit against Gilead in a bid to ground the drug. Read More
India’s Ministry of Health and Family Welfare on Friday began releasing data about drugmakers’ payouts in cases where clinical trial subjects died during a trial, with the first wave of published data focusing on payouts for trial-related deaths between 2010 and 2013. Read More
Amarin has received more bad news from the FDA, which granted its prescription fish oil pill just three years of exclusivity instead of five — a decision limiting market power for the drug as it struggles to win an expanded indication. Read More
Endo Pharmaceuticals, as part of a $192.7 million settlement, has agreed to enter into a five-year corporate integrity agreement (CIA) with HHS to resolve marketing violations surrounding its painkiller Lidoderm. Read More
Republican House members introduce legislation to combat prescription drug abuse through partnerships between industry, retail and government. Read More